Updates in diagnosis and treatment of pediatric antiphospholipid syndrome.

IF 5.7 2区医学 Q1 RHEUMATOLOGY

Current Rheumatology Reports Pub Date : 2024-10-01 Epub Date: 2024-07-24 DOI:10.1007/s11926-024-01156-7

Lucia M Campos, Paula S Marra, Clara R Doria, Sebastian D Cordoba, Clovis A Silva

{"title":"Updates in diagnosis and treatment of pediatric antiphospholipid syndrome.","authors":"Lucia M Campos, Paula S Marra, Clara R Doria, Sebastian D Cordoba, Clovis A Silva","doi":"10.1007/s11926-024-01156-7","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review offers an overview of the most important recent articles on pediatric APS.Recent findings: Non-thrombotic extra criteria manifestations were prevalent in pediatric APS. Pregnancy morbidity has been described as the first manifestation of APS at youth age, impairing gestational outcomes. The 2023 APS criteria were developed for adult APS patients, and there is still a lack of pediatric-specific APS criteria. Catastrophic APS was more commonly reported as the initial manifestation of pediatric APS than in adults. Regarding treatment, direct oral anticoagulants have been recently approval for pediatric patients with venous thrombosis. New approaches have been proposed for severe cases, for arterial thrombosis, and rituximab for refractory cases. Recurrences typically occurred early and were associated with older age at diagnosis. Current studies highlighted the multifaceted nature of pediatric APS. Further large prospective multicenter studies evaluating new medications capable of reducing recurrence risk and improving prognosis in this population will be required.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"366-374"},"PeriodicalIF":5.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Rheumatology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11926-024-01156-7","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review offers an overview of the most important recent articles on pediatric APS.

Recent findings: Non-thrombotic extra criteria manifestations were prevalent in pediatric APS. Pregnancy morbidity has been described as the first manifestation of APS at youth age, impairing gestational outcomes. The 2023 APS criteria were developed for adult APS patients, and there is still a lack of pediatric-specific APS criteria. Catastrophic APS was more commonly reported as the initial manifestation of pediatric APS than in adults. Regarding treatment, direct oral anticoagulants have been recently approval for pediatric patients with venous thrombosis. New approaches have been proposed for severe cases, for arterial thrombosis, and rituximab for refractory cases. Recurrences typically occurred early and were associated with older age at diagnosis. Current studies highlighted the multifaceted nature of pediatric APS. Further large prospective multicenter studies evaluating new medications capable of reducing recurrence risk and improving prognosis in this population will be required.

查看原文本刊更多论文

诊断和治疗小儿抗磷脂综合征的最新进展。

综述目的：本综述概述了近期有关小儿 APS 的最重要文章：非血栓性标准外表现在小儿APS中十分普遍。妊娠期发病被描述为青少年 APS 的首发表现，会损害妊娠结局。2023 年 APS 标准是针对成人 APS 患者制定的，目前仍缺乏针对儿科的 APS 标准。与成人相比，灾难性 APS 更常被报告为儿科 APS 的初始表现。在治疗方面，直接口服抗凝剂最近已被批准用于静脉血栓形成的儿科患者。针对严重病例、动脉血栓形成和难治性病例的利妥昔单抗，也提出了新的治疗方法。复发通常发生在早期，与诊断时年龄较大有关。目前的研究强调了儿科 APS 的多面性。需要进一步开展大型前瞻性多中心研究，评估能够降低复发风险和改善该人群预后的新药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Rheumatology Reports RHEUMATOLOGY-

CiteScore

11.20

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published research in the field of rheumatology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of rheumatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas such as the many forms of arthritis, osteoporosis and metabolic bone disease, and systemic lupus erythematosus. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also occasionally provided.